Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05402254
Other study ID # EI-FC-2022-03
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2022
Est. completion date December 30, 2023

Study information

Verified date August 2022
Source Hospital San Carlos, Madrid
Contact Natalia Rodriguez
Phone 627551464
Email nrgalan@salud.madrid.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HYPOTHESIS An advanced practice nursing intervention in the area of pharmacovigilance performed on patients and professionals improves the identification and reporting of suspected adverse drug reactions (ADR) and improves the overall experience of hospitalized patients.


Description:

PRIMARY OBJETIVES 1. To assess whether an advanced nursing intervention improves the identification and reporting of suspected ADR. SECONDARY OBJECTIVES 1. To determine if an advanced nursing intervention improves the experience related to the use of medications measured through the QExPac-21 patient experience questionnaire. 2. Identify which factors associated with medications increase the risk of ADRs and the characteristics of the patients. 3. Know the incidence and describe ADRs: severity, preventability, and causality using validated scales. 4. Describe the degree of nursing intervention according to the North American Nursing Diagnosis Association (NANDA) Taxonomy, and the classification of nursing interventions (NIC) Related to drug use. 5. Quantify the number of interconsultation generated by patients and professionals related to the use of drugs. 6. Determine the degree of adherence and compliance with the regimens prescribed to the patients. STUDY DESIGN Prospective, randomized and controlled study of an intervention that compares a group of patients according to the usual practice of the nursing care process, against another on which a more intensive nursing intervention is carried out for the identification and notification of ADRs. It is carried out on a representative sample of patients admitted to a tertiary level hospital with 860 beds of the Madrid Health Service during the year 2022.


Recruitment information / eligibility

Status Recruiting
Enrollment 394
Est. completion date December 30, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Patients with pharmacological treatment. 2. Patients of both sexes aged between 0 and 100 years. 3. Patients admitted to medical or surgical hospitalization units or emergency services for at least 24 hours. 4. Patients who have received the information and agreed to participate in the study. Exclusion Criteria: 1. Patients included in other clinical trials or drug studies at the time of selection. 2. Patients with significant cognitive impairment, without adequate family support or primary caregiver. 3. Patients and/or caregivers who, once offered to participate in the study, do not give their consent 4. Impossibility of communication due to language barriers or other biopsychosocial problems.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pharmacovigilance Program
Knowledge of the risks in the use of the drug, identification and notification of ADE

Locations

Country Name City State
Spain Hospital San Carlos Madrid

Sponsors (1)

Lead Sponsor Collaborator
Hospital San Carlos, Madrid

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse drug event Number of identified adverse drug event Seven months
See also
  Status Clinical Trial Phase
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT05007041 - Simultaneous RZV and aIIV4 Vaccination Phase 4
Suspended NCT02559960 - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Completed NCT03112083 - Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure N/A
Completed NCT05028361 - Simultaneous mRNA COVID-19 and IIV4 Vaccination Study Phase 4
Completed NCT04284553 - Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults N/A
Recruiting NCT06120712 - A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) Phase 1/Phase 2
Completed NCT04181775 - Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
Completed NCT02906657 - Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly N/A
Completed NCT03640273 - Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients Phase 2
Completed NCT02162147 - How Safe Are Our Pediatric Emergency Departments? N/A
Completed NCT01897870 - The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge. N/A
Completed NCT03725046 - Impact of an Optimized Communication on the Readmission for Adverse Drug Event N/A
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT05538065 - NUDGE-EHR Replication Trial at Mass General Brigham N/A
Completed NCT03442010 - Adverse Drug Events at Emergency Department
Recruiting NCT04791150 - Rheumatologic Adverse Events and Cancer Immunotherapy N/A
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A